Compensation

The Remuneration Policy was adopted at the March 29, 2023 Annual General Meeting and was subsequently amended by the Board of Directors on August 3, 2023, as a consequence of the amendment of The Nasdaq Stock Market LLC Listing Rules regarding clawback standards. Additionally, the Compensation Report is available and describes the details of the compensation of the Board of Directors of Genmab A/S and our Executive Management officers in respect of the financial year 2022. The decisions made by the Board of Directors were made in accordance with the then effective Remuneration Policy. The 2022 Compensation Report has been prepared in compliance with section 139b of the Danish Companies Act. The Compensation Report also includes disclosures that are not required by law but that Genmab thinks are helpful for shareholders to understand Genmab A/S’ approach to executive compensation and Board of Directors’ compensation.